Comparison of the International Association of Diabetes in Pregnancy Study Group Criteria with the Old American Diabetes Association Criteria for Diagnosis of Gestational Diabetes Mellitus

Mahtab Niroomand 1, *, Jamileh Afsar 2, Farhad Hosseinpanah 3, Maryam Afrakhteh 4, Farah Farzaneh 5 and Sara Serahati 3

1 Endocrinology Division, Department of Internal Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 Department of Internal Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3 Obesity Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4 Department of Obstetrics and Gynecology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
5 Department of Obstetrics and Gynecology, Gynecology Cancer Research Center, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

* Corresponding author: Endocrinology Division, Department of Internal Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Email: mahtabinroomand@yahoo.com

Received 2018 December 28; Revised 2019 September 04; Accepted 2019 September 07.

Abstract

Objectives: This study aimed to assess the prevalence of gestational diabetes mellitus (GDM) based on two sets of criteria, namely the old criteria suggested in 2009 by the American Diabetes Association and new criteria of the International Association of Diabetes in Pregnancy Study Group. We also evaluated the predictive power of the risk factors of GDM.

Methods: Pregnant women from three outpatient clinics in Tehran, Iran, participated in this cross-sectional observational study. During the first perinatal visit, demographic data, medical histories, weight, and height of mothers were recorded. The mother’s fasting glucose and glycosylated hemoglobin were measured. An oral glucose tolerance test was also performed. The prevalence of GDM, based on the two criteria, was estimated and its predictive factors were investigated.

Results: Of 1,117 pregnant women, 156 (15.6%) and 71 (7.1%) patients had GDM based on the new and old criteria, respectively. Multivariate analysis showed that older age at pregnancy (OR = 1.05; 95% CI: 1.006 - 1.107; P = 0.03), higher body mass index (OR = 1.2; 95% CI: 1.15 - 1.3; P < 0.001), family history of diabetes (OR = 1.97; 95% CI: 1.11 - 3.5; P = 0.02), and history of macrosomia (OR = 7.8; 95% CI: 1.96 - 30.9; P = 0.004) were independent predictive factors for GDM.

Conclusions: Using the new criteria, the prevalence of GDM increases by 2.2 folds compared to the old criteria. Several factors can independently predict the occurrence of GDM.

Keywords: Gestational Diabetes Mellitus, Prevalence, Predictive Factors, Pregnancy

1. Background

Gestational diabetes mellitus (GDM) is defined as hyperglycemia at any time in pregnancy based on defined thresholds that are lower than those considered for overt diabetes (1, 2). It is the most common metabolic disorder during pregnancy, with a total prevalence of about 7%. However, depending on the study population and diagnostic criteria, higher prevalence rates have also been reported (3, 4). Different studies have reported that a family history of type II diabetes mellitus (DM), GDM in previous pregnancies, giving birth to a child with macrosomia, body mass index (BMI) > 30 kg/m², idiopathic intrauterine fetal death (IUFD), and maternal age > 35 are among the risk factors of developing GDM (5).

Although most women recover after delivery, the tight control of GDM is associated with lower pregnancy and infant complications. Furthermore, the diagnosis of GDM can initiate interventions to decrease the later risk of developing diabetes or at least its early diagnose in case it occurs (6). Hence, the early detection of GDM is essential to avoid complications. Cost-effectiveness studies have shown that screening, diagnosis, and treatment of GDM can improve pregnancy outcomes and are, therefore, cost-effective, regardless of the type of treatment (7).

Different methods and time frames have been proposed for the diagnosis of GDM (Table 1), but there is still a great debate over the best approach (6). Changes in diagnostic criteria shift their sensitivity and specificity and consequently the number of pregnant women who are di-
agdosed with GDM. Based on the results of the HAPO study, a new method for the diagnosis of GDM has been adopted by the American Diabetes Association (ADA). The so-called International Association of Diabetes in Pregnancy Study Group (IADPSG) criteria are better correlated with disease complications in the fetus, infant, and mother. This method has resulted in a 2 to 3-fold increases in the prevalence of diagnosed GDM (8-10). While some researchers have criticized this fact, others believe that due to the number of cases that can easily be controlled with lifestyle changes, the new method reduces the complications of GDM at a lower cost (11).

2. Objectives

Our study aimed to evaluate the effect of IADPSG criteria on the prevalence of diagnosed GDM; we also sought to evaluate the predictive power of each risk factor of GDM.

3. Methods

3.1. Study Population

This was a cross-sectional study. The study population included pregnant women aged 18 years or older who visited the obstetrics and gynecology clinics of three university-affiliated hospitals in Tehran between October 2011 and November 2012. The exclusion criteria were an unwillingness to participate in the study, failure to complete the Glucose Tolerance Test (GTT), having an pregnancy with assisted reproductive technology, and a history of overt diabetes before the index pregnancy. Moreover, pregnant women consuming medications effective on glucose metabolism, patients with chronic liver disease, and those with endocrine disorders were excluded from the study. The University Ethics Committee approved the study protocol. All patients signed informed consent forms. Considering the GDM prevalence of 14%, α = 0.05, and accuracy of 5%, the sample size was calculated to be around 1100 women that were selected using consecutive sampling.

3.2. Data Collection

Demographic and clinical data were obtained during 10-min interviews, including age, smoking, alcohol consumption, history of hypertension, gestational hypertension, diabetes in first degree relatives or in previous pregnancies, polycystic ovary syndrome (PCOS), having a low-birthweight infant, macrosomia, and abortion. When a clear history of PCOS was absent, we obtained the history of signs and symptoms of androgen excess (including acne or hirsutism) and ovarian dysfunction. All interviews were conducted by either of the three researchers (MA, FF, and MN). The weight without shoes and with a light dress at the first prenatal visit (before 24 weeks of gestational age) was measured by a trained nurse using a standard digital scale (Seca, Hamburg, Germany) with an accuracy of 0.1 Kg. Height was measured without shoes and with a standard wall Stadiometer (Seca) with an accuracy of 0.1 cm. Blood pressure was measured twice by trained staff after a 15-min rest, in the sitting position, using a standard mercury sphygmomanometer with an accuracy of 1 mmHg. Gestational age was calculated based on the last menstrual period. If the exact date was not specified, the time of delivery was calculated based on sonographic evaluation (between weeks 6 and 28 of pregnancy). To check the fasting glucose and glycosylated hemoglobin, a blood sample was taken from the mother after 8-h fasting in the first prenatal visit.

For mothers whose overt diabetes was ruled out at the first prenatal visit, a standard oral glucose tolerance test (OGTT) was performed between 24 and 28 weeks of gestation. All evaluations were performed using an enzymatic method. A blood glucose test was performed using Enzymatic Glucose Oxidase Method and the coefficient of variation (CV) was below 5%.

3.3. Diagnostic Protocols

The old ADA criteria and new IADPSG criteria were used separately for the diagnosis of GDM. Based on the old ADA criteria (2009), OGTT with 75 g of glucose was performed from 24th to 28th weeks of gestation and if two measurements were higher than the recommended cut points (FPG ≥ 95, 1hPG ≥ 180, 2hPG ≥ 153), GDM was diagnosed. In the IADPSG criteria, 75 g OGTT was performed and if only one plasma glucose reading was higher than the recommended cut point (FPG ≥ 92, 1hPG ≥ 180, 2hPG ≥ 153), the diagnosis of GDM was confirmed (1, 12). The ADA criteria (FPG ≥ 126 mg/dL or HgbA1C ≥ 6.5%) were used for the diagnosis of overt diabetes.

3.4. Statistical Analysis

All continuous variables were checked for normal distribution, using Kolmogorov-Smirnov and Shapiro-Wilk tests. All normally distributed data are expressed as mean ± SD and skewed continuous variables are expressed as median (IQ 25 - 75). Categorical variables are shown as frequency (percentage). Pearson chi-square test, one-way ANOVA with LSD post hoc test, and Kruskal Wallis test with pairwise comparisons were used to compare between-group differences for categorical variables, normally distributed variables, and skewed continuous variables, respectively. After using the logistic regression model, clinical and demographic variables associated with GDM (according to the IADPSG criteria) with P values of less than
Table 1. Diagnostic Criteria for GDM

| Criteria | 75 g OGTT (IADPSG Criteria) | 75 g OGTT (ADA Criteria 2009) | 100 g OGTT (Carpenter and Coustan Criteria) | 100 g OGTT (NDDG Criteria) |
|----------|-----------------------------|-------------------------------|-----------------------------------------------|-----------------------------|
| Number of abnormal values needed for diagnosis | ≥ 1                          | ≥ 2                           | ≥ 2                                           | ≥ 2                         |
| FPG, mg/dL | 92                           | 95                            | 95                                            | 105                         |
| 1st PG, mg/dL | 180                          | 180                           | 180                                           | 180                         |
| 2nd PG, mg/dL | 153                          | 155                           | 155                                           | 165                         |
| 3rd PG, mg/dL | 140                          | 145                           |                                               |                             |

Abbreviations: FPG, fasting plasma glucose; GDM, gestational diabetes mellitus; IADPSG, International Association of Diabetes in Pregnancy Study Group; NDDG, National Diabetes Data Group; OGTT, oral glucose tolerance test; PG, plasma glucose.

0.2 in univariate analysis were considered for multivariate analysis. Multivariate logistic regression with backward stepwise selection procedures was used to estimate the adjusted odds ratios and 95% confidence intervals of different variables. All analyses were performed using IBM SPSS version 20 for Windows (SPSS, Chicago, IL, USA), with a two-tailed P value of < 0.05 considered significant.

4. Results

We studied a total number of 1117 pregnant women. Their mean age was 26.4 ± 4.2 years. Of them, 537 (48.1%) women were primigravid, 380 (34.1%) women were gravid 2, and 144 (12.9%) women were gravid 3. The family history of DM was positive in 108 (9.7%) women and 12 (1.1%) women had a history of impaired FPG or IGT. Table 2 shows the demographic and clinical characteristics of the study subjects. The mean gestational age at the first prenatal visit was 12.2 ± 5.9 weeks in total, and 11.5 ± 3.4, 12.4 ± 5.2, and 12.3 ± 6.1 weeks in patients with overt diabetes, those with GDM, and those without GDM, respectively.

Moreover, 39 (2.95%) women had overt DM in their first prenatal visits. Of 1084 pregnant women who did not have overt diabetes at first visit, 93 did not return for further evaluation at weeks 24 - 28 of pregnancy and were not followed up. GTT was performed for the remaining 991 participants. Based on the old ADA criteria (having two plasma glucose measurements of above the specified values), 71 had GDM and the calculated prevalence of GDM was 7.1% (Figure 1).

Based on the IADPSG criteria, 156 patients were diagnosed as having GDM and the prevalence of GDM was 15.7% (Figure 1). In 84.7% of these patients, the diagnosis was made by the FPG criteria.

Univariate analysis showed that a history of abortion (P < 0.001), macrosomia (P < 0.001), history of GDM (P < 0.001), impaired FPG or IGT (P = 0.01), family history of DM (P = 0.004), and history of hypertension (P < 0.001), BMI and weight (P < 0.001) were the factors associated with GDM (Table 3). In addition, the FPG level had a significant correlation with the risk of developing GDM (P < 0.001) (Table 3).

Multivariate logistic regression analysis showed that age at pregnancy, BMI, family history of diabetes, and history of macrosomia in previous pregnancies were independent predictive factors of GDM after adjusting for other factors. Among these factors, the history of macrosomia in previous pregnancies was associated with an increased risk of GDM (Table 4).

5. Discussion

This study aimed to assess the prevalence of GDM based on the IADPSG and old ADA criteria simultaneously. We found that the prevalence of GDM was 2.2 times higher based on the IADPSG criteria than based on the old ADA criteria (7.1%). In addition, it was shown that pregnancy at an older age, high BMI, family history of diabetes, and history of macrosomia in previous pregnancies were predictive factors for developing GDM.

The prevalence of GDM varies in different societies and ranges from 1% to 14% (13). This variation in prevalence mainly results from geographic and demographic factors, as well as differences in diagnostic criteria (3). Two studies in Brazil and Norway, using IADPSG criteria, reported a prevalence of 18% and 31.5%, respectively (14, 15). Reports of the prevalence of GDM in Iran have also shown different results (16-19). In a systematic review of studies between 1992 and 2007, the prevalence of GDM in different areas of Iran was reported to be between 1.3 and 8.9% (20). None of these studies applied the IADPSG criteria. In 2012, a single-center small study in Iran reported a prevalence of 31% based on the IADPSG criteria (16).

Different criteria are used for the diagnosis of GDM, each having its own accuracy and sensitivity, leading to variations in the reported prevalence of GDM (3). The WHO...
criteria for the diagnosis of GDM are more sensitive than the National Diabetes Data Group (NDDG) and ADA criteria (6). Other studies also suggest that the ADA criteria are more sensitive than NDDG for the diagnosis of IGT (21). In a multicenter study of 25,000 pregnant women using the IADPSG criteria, the GDM prevalence was reported as 17.8% (22). In a study by Agarawal et al. in the United Arab Emirates in 2010, the GDM prevalence based on the new criteria showed a 3-fold increase (10). In a study by Sacks et al. in 2012, the GDM prevalence at 15 centers was evaluated. They showed that the prevalence was 17.8%, ranging from 9.3% to 25.5% (23). In another study in Australia on 1,275 pregnant women by Moses et al., the GDM prevalence was reported as 9.6% and 13% based on the old and new criteria, respectively (24). In 2011, in another study of 607 Indian pregnant women, the GDM prevalence was 7.1% based on the old criteria and 10.8% based on the new criteria (25).

The present study of GDM used the old ADA and new IADPSG criteria simultaneously, making it possible to compare the prevalence of GDM based on these criteria with

| Table 2. Demographic and Clinical Characteristics of the Participantsa |
|-------------------|-----------------|-----------------|-----------------|-------------|-------------|-------------|
| Variable          | Total (N = 1117) | Overt DM (N = 33) | GDM (+) (N = 156) | GDM (-) (N = 835) | Pb          | Pc          | Pd          |
| Age, y            | 26.5 ± 4.2      | 27.7 ± 5.1      | 28.7 ± 4.8        | 26.05 ± 3.9        | < 0.001     | 0.024       | < 0.001     |
| Gravidity         | 2 (1 - 2)       | 2 (1 - 3)       | 2 (1 - 3)         | 1 (1 - 2)          | < 0.001     | 0.010       | < 0.001     |
| BMI, Kg/m²        | 27.5 ± 6.1      | 27.5 ± 3.8      | 27.3 ± 4.6        | 25.0 ± 2.8         | < 0.001     | < 0.001     | < 0.001     |
| Pregnancy weight gain, Kg | 5.6 ± 2.0    | 9.2 ± 1.8       | 8.0 ± 2.1         | 5.2 ± 1.6          | < 0.001     | < 0.001     | < 0.001     |
| SBP, mmHg         | 113.2 ± 10.3    | 117.5 ± 10.7    | 118.2 ± 11.3      | 112.4 ± 9.9        | < 0.001     | 0.026       | < 0.001     |
| DBP, mmHg         | 71.0 ± 8.1      | 72.0 ± 9.4      | 72.8 ± 8.9        | 70.7 ± 7.9         | 0.049       | 0.490       | 0.007       |
| FPG, mg/dL        | 80.4 ± 11.2     | 116.3 ± 16.5    | 93.8 ± 8.5        | 76.5 ± 5.7         | < 0.001     | < 0.001     | < 0.001     |
| HbA1C, %          | 4.7 ± 0.7       | 6.8 ± 0.3       | 5.4 ± 0.6         | 4.5 ± 0.6          | < 0.001     | < 0.001     | < 0.001     |
| Hemoglobin, g/dL  | 12.4 ± 0.9      | 12.7 ± 0.8      | 12.4 ± 1.5        | 12.4 ± 0.8         | 0.399       | 0.087       | 0.911       |

Abbreviations: BMI, body mass index; DBP, diastolic blood pressure (during the first prenatal visit); FPG, fasting plasma glucose (during the first prenatal visit); GDM, gestational diabetes mellitus; SBP, systolic blood pressure (during the first prenatal visit)
aValues are expressed as mean ± standard deviation or median (IQR 25 - 75).
bP value among groups
cP value between overt DM and GDM (-)
dP value between GDM (-) and GDM (+)

| Table 3. Past History and Biochemical Characteristics of Participants with and Without GDM |
|-------------------------------|-----------------|-----------------|-----------------|-------------|
| Variable                      | GDM (%)         | No (N = 848)    | Yes (N = 156)   | P            |
| Past history, No. (%)         |                 |                 |                 |              |
| History of abortion           | 74 (8.7)        | 42 (27.1)       | < 0.001         |
| History of macrosomia         | 0 (0.0)         | 7 (4.5)         | < 0.001         |
| History of congenital malformation | 1 (0.1)    | 0 (0.0)         | 0.845           |
| History of GDM                | 1 (0.1)         | 9 (5.8)         | < 0.001         |
| History of IFG or IGT         | 0 (0.0)         | 5 (3.2)         | < 0.001         |
| Family history of DM          | 68 (8.0)        | 27 (17.4)       | < 0.001         |
| History of HTN                | 1 (0.1)         | 3 (1.9)         | 0.031           |
| Biochemical characteristics, mean ± SD |                 |                 |                 |              |
| Hemoglobin, g/dL              | 12.4 ± 0.8      | 12.4 ± 1.4      | 0.953           |
| FPG, mg/dL                    | 76.5 ± 5.7      | 93.9 ± 8.5      | < 0.001         |
| Weight gain, kg               | 5.2 ± 1.6       | 8.0 ± 2.0       | < 0.001         |
| BMI, kg/m²                    | 25.0 ± 2.8      | 27.3 ± 4.6      | < 0.001         |

Abbreviations: BMI, body mass index; DM, diabetes mellitus; FPG, fasting plasma glucose; GDM, gestational diabetes mellitus; HTN, hypertension; IFG, impaired fasting glucose; IGT, impaired glucose tolerance
1117 pregnant women screened

33 women had overt diabetes

1084 participants were included

93 were lost to follow up at 24-28 weeks

991 underwent 75 gram OGTT

Analyzed based on old ADA criteria

71 had GDM
920 were GDM (-)ve

Analyzed based on IADPSG criteria

156 had GDM
835 were GDM (-)ve

Figure 1. Flow diagram illustrating the recruitment and evaluation of participants in the study. GDM: gestational diabetes mellitus; OGTT: oral glucose tolerance test, IADPSG: International Association of Diabetes in Pregnancy Study Group, ADA: American Diabetes Association

high accuracy. The IADPSG criteria are more sensitive to the screening of GDM. As an example, Shang and Lin reported a prevalence of 37.7% for GDM based on the IADPSG criteria and a prevalence of 12.9% based on the old ADA criteria. GDM, as diagnosed by IADPSG, had a greater association with the complications of the disease (9). In some studies, the results of IADPSG for the diagnosis of GDM were similar to diagnostic methods approved by the WHO (26). However, most studies have shown that using the IADPSG criteria, there would be a 2 to 3-fold increases in the GDM prevalence (9, 10). A recently published meta-analysis showed that studies that used the IADPSG criteria reported a significantly higher prevalence of GDM (6-11 folds) compared to other studies (3).

Various risk factors have been suggested for the development of GDM in previous studies. BMI has been reported in prior studies to be a predictive factor for GDM. In the present study, we also found that higher BMI at the beginning of pregnancy and more weight gain during pregnancy were the risk factors for GDM. The reduction of insulin sensitivity among obese pregnancies can justify this relationship. This obesity-related insulin resistance in-
increases the normal glucose levels (27). This finding emphasizes the importance of weight control strategies, especially during pregnancy. In addition, our study showed the family history of diabetes, history of macrosomia, history of GDM in previous pregnancies, abortion, and impaired GTT to be the independent risk factors for GDM. Moreover, there was a significant correlation between age and onset of GDM. Macrosomia during index pregnancy may indicate poor maternal diet or GDM severity. This, in turn, predisposes the mother to recurrent GDM (28). The predisposing effect of a history of GDM may result from a "shared risk factor" in repeated pregnancies (29). Miscarriage during index pregnancy may point to the presence of various endocrine pathologies or poor blood glucose control. These may affect the normal metabolism of insulin, hence predisposing the mother to GDM (30). In line with the findings of this study, Teh et al. reported that a history of GDM and BMI of above 35 are two independent risk factors for GDM (31). However, Teede et al. reported that a history of GDM, higher maternal age and BMI, and a family history of diabetes were the most important risk factors for GDM (32). Four previous studies have shown that a family history of diabetes, history of GDM, higher maternal age, and BMI are the main risk factors for GDM (33-35).

In addition, although pregnant women at risk of GDM often receive training on lifestyle change and diet to control their weight, studies have shown that the diagnosis of GDM is an important factor in reaching the desired weight for these mothers (36). The awareness of diabetes creates a motivation to take more serious measures to adjust the lifestyle (37). Thus, early diagnosis and quick management of GDM is of great importance. Using IADPSG criteria, which are more sensitive for the diagnosis of GDM, is a better screening test for this purpose.

Our study faces some limitations. We did not evaluate the clinical outcomes of GDM in this study. Furthermore, due to its observational nature, the complete elimination of biases including "referral bias" was not possible. We did not have access to the pre-pregnancy weight of the participants and thus we assumed that this measurement was the best estimate of their pre-pregnancy BMI that we could have under study conditions. Moreover, the diagnosis of PCOS was mainly based on self-report.

However, our study, applied both criteria for the diagnosis of GDM simultaneously, which made it possible to compare the prevalence of GDM based on these criteria with high precision. The sample size was also large (>1,000 participants).

Using the IADPSG criteria, a higher number of mothers who would otherwise be considered as healthy by the old criteria were diagnosed with GDM and received early treatment for the prevention of its complications. This may render this set of criteria more favorable. However, medicalization of pregnancy due to the higher rate of GDM is one of the disadvantages of using IADPSG criteria. In addition, our study did not evaluate the effect of criteria on perinatal outcomes. Thus, we cannot recommend one of the criteria over another. The study of different risk factors and analysis of the effect of each factor on the prediction of GDM development can help us diagnose at-risk individuals for whom the GTT is either not available or not feasible. In addition, this study may be considered a start for the recognition of the power of each risk factor in GDM incidence.

According to the findings of the present study, the prevalence of GDM showed a 2.2-fold increase when the IADPSG criteria were applied in lieu of the old criteria. It was also shown that increased maternal BMI and age, family history of diabetes, history of GDM, and macrosomia in pregnancies are the risk factors for GDM.

Acknowledgments

The authors would like to thank the staff of Perinatology Clinics at Shohada-E-Tajrish Hospital, Taleghani Hospital, and Imam Hossein Hospital.

Footnotes

Authors’ Contribution: Mahtab Niroomand conceived the idea and wrote the first draft of the paper. Jamileh Afsar and Mahtab Niroomand conducted the literature search. Maryam Afarkhte, Jamileh Afsar, and Farah Farzaneh collected data. Sara Serahati and Farhad Hosseinpanah performed the statistical analysis. Mahtab Niroomand supervised data collection. Farhad Hosseinpanah critically reviewed the first draft. All the authors provided input for the paper and approved the final version.

Conflict of Interests: The authors have no conflict of interest.

Table 4. Independent Risk Factors for the Prediction of Gestational Diabetes Mellitus (Multivariate Analysis)

| Variable                  | OR (95% CI) | P Value |
|---------------------------|-------------|---------|
| Age                       | 1.09 (1.04 - 1.13) | < 0.001 |
| BMI                       | 1.2 (1.11 - 1.25) | < 0.001 |
| History of macrosomia     | 6.78 (1.73 - 26.6) | 0.006   |
| Family history of DM      | 2.01 (1.18 - 3.41) | 0.01    |
| History of GDM            | 1.07 (0.31 - 3.68) | 0.9     |
| History of PCOS           | 1.72 (0.67 - 4.40) | 0.25    |

Abbreviations: BMI, body mass index; CI, confidence interval; DM, diabetes mellitus; OR, odds ratio; PCOS, polycystic ovarian syndrome
Agarwal MM, Dhatt GS, Shah SM. Gestational diabetes mellitus: All patients signed informed consent form.

Funding/Support: This study was funded by the Shahid Beheshti University of Medical Sciences.

Patient Consent: All patients signed informed consent forms.

References

1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2009;32 Suppl 1:S62-7. doi: 10.2337/dc09-0502. [PubMed: 19182895]. [PubMed Central: PMC2503514].

2. World Health Organization. Classification of diabetes mellitus. World Health Organization; 2019. Available from: https://apps.who.int/iris/handle/10665/325152.

3. Behboudi-Gandevani S, Amir M, Bidhendi Yarandi R, Ramezani Tehrani F. The impact of diagnostic criteria for gestational diabetes on its prevalence: A systematic review and meta-analysis. Diabetes Metab Syndr. 2019;13(11). doi: 10.1016/j.dsx.2019.04.010. [PubMed: 30733832]. [PubMed Central: PMC6359830].

4. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37 Suppl 1:S81-90. doi: 10.2373/diabetes.114-S081. [PubMed: 24357215].

5. Catalano PM, McIntyre HD, Cruickshank JK, McCance DR, Dyer AR, Metzger BE, et al. The hyperglycemia and adverse pregnancy outcome study: Associations of GDM and obesity with pregnancy outcomes. Diabetes Care. 2012;35(4):778–80. doi: 10.2337/dc11-1790. [PubMed: 22357878]. [PubMed Central: PMC3308090].

6. Ratner RE. Prevention of type 2 diabetes in women with previous gestational diabetes. Diabetes Care. 2007;30 Suppl 2:S242–5. doi: 10.2337/dctd07-0223. [PubMed: 17596479].

7. National Institute for Health and Clinical Excellence. Cost-effectiveness of screening, diagnosis and treatment for gestational diabetes. 2008. NAP p.

8. Hadar E, Yoge y. Translating the HAPO study into new diagnostic criteria for GDM? From HAPO to IADPSG and back to O'Sullivan. Diabetes Care. 2010;33(4):553–4. doi: 10.2337/dc09-0457. [PubMed: 20509529].

9. Shang M, Lin L. IADPSG criteria for diagnosing gestational diabetes mellitus and predicting adverse pregnancy outcomes. J Perinatol. 2014;34(2):100–4. doi: 10.1038/jp.2013.143. [PubMed: 24232664].

10. Agarwal MM, Dhatt GS, Shah SM. Gestational diabetes mellitus: Simplifying the international association of diabetes and pregnancy diagnostic algorithm using fasting plasma glucose. Diabetes Care. 2010;33(9):2018–20. doi: 10.2337/dc10-0572. [PubMed: 20509544]. [PubMed Central: PMC2928355].

11. Visser GH, de Valk HW. Is the evidence strong enough to change the diagnostic criteria for gestational diabetes now? Am J Obstet Gynecol. 2013;209(4):2460–4. doi: 10.1016/j.ajog.2012.10.881. [PubMed: 23101371].

12. Coustan DR, Lowe LP, Metzger BE, Dyer AR. International Association of Diabetes and Pregnancy Study Groups. The hyperglycemia and adverse pregnancy outcome (HAPO) study: Paving the way for new diagnostic criteria for gestational diabetes mellitus. Am J Obstet Gynecol. 2010;202(6):5354–6. doi: 10.1016/j.ajog.2010.04.006. [PubMed: 20509577]. [PubMed Central: PMC2897007].

13. American Diabetes Association. Gestational diabetes mellitus. Diabetes Care. 2004;27 Suppl 1:S88–90. doi: 10.2337/diacare.27.2007.s88. [PubMed: 14693936].

14. Sommer C, Morkrid K, Jenum AK, Sletten I, Mosdol A, Birkeland KL. Weight gain, total fat gain and regional fat gain during pregnancy and the association with gestational diabetes: A population-based cohort study. Int J Obes (Lond). 2014;38(1):76–81. doi: 10.1038/ijo.2013.185. [PubMed: 24051501].

15. Trujillo J, Vigo A, Duncan BB, Falavigna M, Wendland EM, Campos MA, et al. Impact of the International Association of Diabetes and Pregnancy Study Groups criteria for gestational diabetes. Diabetes Res Clin Pract. 2015;108(2):228–95. doi: 10.1016/j.diabres.2015.02.007. [PubMed: 25765668].

16. Moradi S, Shafeeepour MR, Mortazavi M, Pishgar F. Prevalence of gestational diabetes mellitus in Rafsanjan: A comparison of different criteria. Med J Islam Repub Iran. 2015;29:209. [PubMed: 26577277]. [PubMed Central: PMC447629].

17. Hadaegh F, Kheyri Andish M, Rahimi S, Touhid M. Prevalence of gestational diabetes in pregnant women of Bandar Abbas. Endocrinol Metab. 2004;19(3):225–33.

18. Tabatabaei A, Fallahi Z, Haghbighi S, Farmani M, Horri N, Eslamian Z, et al. Prevalence and risk factors for gestational diabetes mellitus in pregnant women of Isfahan, Iran. Iran J Endocrinol Metab. 2007;9(3):251–9.

19. Keshavarz M. Prevalence of gestational diabetes mellitus in shahrud township. J Mazandaran Univ Med Sci. 2003;13(4):90–7.

20. Khoshnian Nikoo M, Abbaszadeh Ahranjani S, Larjani B. A review on the prevalence of gestational diabetes mellitus (GDM) in different regions of Iran. Iran J Diabetes Lipid Disorders. 2009;6(7).

21. Santos-Ayarzagotia M, Salinas-Martinez AM, Villarreal-Perey JZ. Gestational diabetes: Validity of ADA and WHO diagnostic criteria using NDDG as the reference test. Diabetes Res Clin Pract. 2006;74(3):322–8. doi: 10.1016/j.diabres.2006.04.005. [PubMed: 16750819].

22. Metzger BE, Gabbe SG, Persson B; International Association of Diabetes and Pregnancy Study Groups Consensus Panel Writing Group; et al. The diagnosis of gestational diabetes mellitus: New paradigms or status quo? J Matern Fetal Neonatal Med. 2012;25(12):2564–9. doi: 10.3109/14767058.2012.78002. [PubMed: 22876884].

23. Sacks DA, Hadden DR, Maresh M, Deerochanawong C, Dyer AR, Metzger BE, et al. Frequency of gestational diabetes mellitus at collaborating centers based on IADPSG consensus panel-recommended criteria: The Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study. Diabetes Care. 2012;35(3):526–8. doi: 10.2337/dc11-1790. [PubMed: 22355019]. [PubMed Central: PMC322761].

24. Moses RG, Morris GJ, Petocz P, San Gil F, Garg D. The impact of potential new diagnostic criteria on the prevalence of gestational diabetes mellitus in Australia. Med J Aust. 2011;194(7):338–40. doi: 10.5694/mja11.10033. [PubMed: 21470082].

25. Rajput R, Yadav Y, Nanda S, Rajput M. Prevalence of gestational diabetes mellitus and associated risk factors at a tertiary care hospital in Haryana. Indian J Med Res. 2013;137(4):728–33. [PubMed: 23703340]. [PubMed Central: PMC3724253].

26. Nayak PK, Mitra S, Sahoo J, Kamalnath S. Comparison of the world health organization and the international association of diabetes and pregnancy study groups criteria in diagnosing gestational diabetes mellitus in South Indians. Indian J Endocrinol Metab. 2014;18(3):431–4. doi: 10.4103/2230-8210.131229. [PubMed: 24944950]. [PubMed Central: PMC4046514].

27. Huda SS, Brodie LE, Sattar N. Obesity in pregnancy: Prevalence and metabolic consequences. Semin Fetal Neonatal Med. 2010;15(2):170–6. doi: 10.1016/j.siny.2009.09.006. [PubMed: 19896913].

28. MacNeill S, Dodds L, Hamilton DC, Arsmoon BA, VandenHof M. Rates and risk factors for recurrence of gestational diabetes. Diabetes Care. 2001;24(4):659–62. doi: 10.2337/diacare.24.4.659. [PubMed: 1130827].

29. Spong CY, Guillermo L, Kuboshige J, Cabalum T. Recurrence of gestational diabetes mellitus: Identification of risk factors. Am J Perinatol. 1998;15(1):29–33. doi: 10.1055/s-1997-991804. [PubMed: 9475804].

30. Muche AA, Olayemi OO, Gete YK. Prevalence and determinants of gestational diabetes mellitus in Africa based on the updated international diagnostic criteria: A systematic review and meta-analysis. Arch Public Health. 2019;77(3):121. doi: 10.1186/s13099-019-0362-0. [PubMed: 31402976]. [PubMed Central: PMC6683510].
31. Teh WT, Teede HJ, Paul E, Harrison CL, Wallace EM, Allan C. Risk factors for gestational diabetes mellitus: Implications for the application of screening guidelines. *Aust N Z J Obstet Gynaecol*. 2011;51(1):26–30. doi: 10.1111/j.1479-828X.2011.01292.x. [PubMed: 21299505].

32. Teede HJ, Harrison CL, Teh WT, Paul E, Allan CA. Gestational diabetes: Development of an early risk prediction tool to facilitate opportunities for prevention. *Aust N Z J Obstet Gynaecol*. 2011;51(6):499–504. doi: 10.1111/j.1479-828X.2011.01356.x. [PubMed: 21951201].

33. Savvidou M, Nelson SM, Makgoba M, Messow CM, Sattar N, Nicolaides K. First-trimester prediction of gestational diabetes mellitus: Examining the potential of combining maternal characteristics and laboratory measures. *Diabetes*. 2010;59(12):3017–22. doi: 10.2337/db10-0688. [PubMed: 20876721]. [PubMed Central: PMC2992761].

34. Gobl CS, Bozkurt I, Rivic P, Schernthaner G, Weitgasser R, Pacini G, et al. A two-step screening algorithm including fasting plasma glucose measurement and a risk estimation model is an accurate strategy for detecting gestational diabetes mellitus. *Diabetologia*. 2012;55(12):373–81. doi: 10.1007/s00125-012-2726-7. [PubMed: 23001377].

35. Nanda S, Savvidou M, Syngelaki A, Akolekar R, Nicolaides KH. Prediction of gestational diabetes mellitus by maternal factors and biomarkers at 11 to 13 weeks. *Prenat Diagn*. 2011;31(2):135–41. doi: 10.1002/pd.2636. [PubMed: 21268010].

36. Metzger BE, Buchanan TA, Coustan DR, de Leiva A, Dunger DB, Hadden DR, et al. Summary and recommendations of the Fifth International Workshop-Conference on Gestational Diabetes Mellitus. *Diabetes Care*. 2007;30 Suppl 2:S251–60. doi: 10.2337/dc07-s225. [PubMed: 17596481].

37. Gastrich MD, Peck S, Janevic T, Bachmann G, Lotwala N, Siyam A. Gestational diabetes mellitus: An educational opportunity. *J Diabetes Nurs*. 2015;17(6):220–4.